Lagadinou et al. (7) further strengthened the mechanism behind the drug resistance and identified that the majority of functionally defined AML LSCs exhibited significantly reduced levels of ROS and higher BCL2 expression. This evidence concerns the gene BCL2 and acute myeloid leukemia.